Whitehawk Expands ADC Cancer Therapy Pipeline
MORRISTOWN, N.J., May 21, 2026 Whitehawk Therapeutics has announced a major expansion of its antibody-drug conjugate (ADC) oncology pipeline...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
MORRISTOWN, N.J., May 21, 2026 Whitehawk Therapeutics has announced a major expansion of its antibody-drug conjugate (ADC) oncology pipeline...
GALWAY, Ireland, May 20, 2026 Medtronic plc has announced its intent to acquire SPR Therapeutics, Inc. in a deal...
